124
Participants
Start Date
November 14, 2017
Primary Completion Date
December 15, 2022
Study Completion Date
December 15, 2022
CT7001
Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression
Fulvestrant
Administered as 2 x 250mg intramuscular (IM) gluteal injections on Day 1, Day 15, Day 28 and every 28 days thereafter.
Research Site 33, Salem
Research Site 37, Tampa
Research Site 39, Columbus
Research Site 47, Cincinnati
Research Site 38, Chicago
Research Site 46, Dallas
Research Site 44, Austin
Research Site 48, Salt Lake City
Research Site 54, Tucson
Research Site 31, Beverly Hills
Research Site 36, Portland
Research Site 34, Boston
Research site 11, Brighton
Research site 5, Cambridge
Research Site 7, Glasgow
Research Site 10, Liverpool
Research Site 9, London
Research Site 8, London
Research Site 3, London
Research Site 1, Manchester
Research Site 4, Manchester
Research Site 2, Oxford
Research Site 6, Southampton
Lead Sponsor
Carrick Therapeutics Limited
INDUSTRY